The human microbiome, comprising trillions of microorganisms in our bodies, plays a key role in maintaining health and preventing diseases. Dysbiosis, or microbial imbalance, significantly increases chronic disease risks. Early microbiome intervention is vital for preventive healthcare as these conditions rise.
Beyond chronic diseases, the microbiome impacts infectious disease management. It serves as a biomarker for infection risk in those with chronic conditions. Microbiome analysis enhances pathogen identification, outbreak characterization, and treatment selection, potentially transforming infectious disease diagnostics.
Despite its immense potential, microbiome analysis remains largely inaccessible to most healthcare practitioners. Current solutions are complex, expensive, and designed primarily for experts, requiring specialized bioinformatics knowledge and IT infrastructure. This hinders routine clinical adoption, limiting the ability of doctors to use microbiome-based diagnostics in patient care.
Our project addresses this challenge through MICK©, a pioneering microbiome analysis platform designed to make scientifically backed microbiome testing widely accessible to healthcare professionals.
MICK is the first platform to offer real-time, automated microbiome analysis, providing evidence-based recommendations for personalized patient care. Unlike existing solutions, MICK:
- Accurately profiles the microbiome, extracting critical insights from sequencing data
- Translates results into patient-specific treatment suggestions, considering phenotypic and genetic factors
- Automates analysis workflows, eliminating the need for coding skills or advanced bioinformatics expertise
- Operates seamlessly across different sequencing technologies, ensuring flexibility and broad adoption
- Supports multiple microbiome types, going beyond traditional gut microbiome testing
- Allows accurate identification of Class B pathogens (IVDR module)
By leveraging cutting-edge microbiome science, MICK contributes to tackling some of the most pressing healthcare challenges in Europe. MICK was developed to:
1.Make microbiome analysis accessible to healthcare professionals, thereby expanding the use of targeted preventive medicine.
2.Bridge the gap between microbiome research and clinical practice, bringing scientific advances from the lab to patient care.
3.Reduce health disparities by enabling wider adoption of microbiome-based diagnostics, improving global health and longevity.
MICK is designed to be used by healthcare professionals, particularly doctors, geneticists, and clinical researchers . By simplifying and democratizing microbiome science, MICK empowers physicians to integrate microbiome-based diagnostics into routine medical practice, enhancing clinical decision-making, particularly for complex conditions.
